The Canadian Cancer Trials Group Central Operations and Statistics Centre will be closed on Friday, July 1, 2016 for Canada Day. Regular business hours will resume on Monday, July 4 at 8:30 am EDT.

Mission

To develop and conduct clinical trials aimed at improving the treatment and prevention of cancer with the ultimate goal of reducing morbidity and mortality from this disease.

About Us

The Canadian Cancer Trials Group is a cooperative oncology group which carries out clinical trials in cancer therapy, supportive care and prevention across Canada and internationally. It is one of the national programmes and networks of the Canadian Cancer Society Research Institute (CCSRI), and is supported by the Canadian Cancer Society (CCS).

Faculty Researchers

Meet the Faculty Researchers

Information

The information contained in this website is intended for use by Canadian Cancer Trials Group members at participating centres.

Recently Activated

  • BRC6 
    A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer
  • CEC6 
    Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
  • I222 
    A Phase I/II Study of the mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Patients with Previously Treated Glioblastoma Multiforme
  • I225 
    A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker
  • I226 
    A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens
  • I229 
    A Phase 1b PD Study of Durvalumab in Patients with HER-2+ Metastatic Breast Cancer Receiving Trastuzumab
  • I231 
    A Phase I/II Study of CX5461
  • MA38 
    Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer
  • MAC18 
    POSITIVE: Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer
  • MEC5 
    A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
  • Planned Trials

  • ALC4 
    A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults.
  • BR35 
    Precision Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (PROMISE-NSCLC): A Randomized Phase II Study Proposal
  • CEC5 
    Corticosteroid with either Bevacizumab or Placebo for Radionecrosis after Surgery for Brain Metastases
  • GA3 
    A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
  • I227 
    A Phase II Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural Mesothelioma
  • I230 
  • I232 
    A Phase II Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Metastatic Castration Resistant Prostate Cancer
  • I233 
  • MA37 
    A Randomized Phase III Trial of Palbociclib with Adjuvant Endocrine Therapy versus Adjuvant Endocrine Therapy alone for HR+/HER2 Negative Early Breast Cancer
  • MAC20 
    Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
  • ME13 
    Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)
  • OVC1 
    A Phase III Single-agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Women with Recurrent Platinum-sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  • OVC2 
    Phase II/III combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
  • PR18 
    TOPARP: Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer
  • REC3 
    A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors Cabozantinib, Crizotinib, Savolitinib, and Sunitinib in Metastatic Papillary Renal Carcinoma (PAPMET)
  • PR19 
    A Randomized Phase II Trial Evaluating Disease Outcome, Acute and Long term Toxicity of High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
  •